The estimated Net Worth of Erich Platzer is at least $330 Thousand dollars as of 16 December 2021. Erich Platzer owns over 100,000 units of Aptose Biosciences Inc stock worth over $186,345 and over the last 21 years he sold APTO stock worth over $43,800. In addition, he makes $99,630 as Independent Director at Aptose Biosciences Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Erich Platzer APTO stock SEC Form 4 insiders trading
Erich has made over 3 trades of the Aptose Biosciences Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 100,000 units of APTO stock worth $138,000 on 16 December 2021.
The largest trade he's ever made was buying 270,000 units of Aptose Biosciences Inc stock on 15 December 2021 worth over $315,900. On average, Erich trades about 32,500 units every 84 days since 2004. As of 16 December 2021 he still owns at least 505,000 units of Aptose Biosciences Inc stock.
You can see the complete history of Erich Platzer stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Erich Platzer biography
Dr. Erich M. Platzer M.D., Ph.D. serves as Independent Director of the Company. In 2001, Dr. Platzer co-founded HBM Healthcare Investments (formerly HBM BioVentures), a global leader in healthcare investing and served as their investment advisor until 2015. Previously, he served as the business director of oncology, as well as the global strategic marketing and therapeutic area head of oncology at Roche, Basel. He also served in various other leadership roles at Roche and was responsible for various strategic corporate partnerships. He has over 12 years of experience in academic medicine and research and was a key member of the team at MSKCC that purified human G-CSF in 1983 (recombinant form: Neupogen®). He earned his M.D. from the Medical School of the University of Erlangen, where he also received his “Dr. med. habil.” (M.D., Ph.D.).
What is the salary of Erich Platzer?
As the Independent Director of Aptose Biosciences Inc, the total compensation of Erich Platzer at Aptose Biosciences Inc is $99,630. There are 11 executives at Aptose Biosciences Inc getting paid more, with William Rice having the highest compensation of $1,511,900.
How old is Erich Platzer?
Erich Platzer is 69, he's been the Independent Director of Aptose Biosciences Inc since 2014. There are 1 older and 11 younger executives at Aptose Biosciences Inc. The oldest executive at Aptose Biosciences Inc is Denis Burger, 75, who is the Lead Independent Director.
What's Erich Platzer's mailing address?
Erich's mailing address filed with the SEC is C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO, A6, M2J 4R3.
Insiders trading at Aptose Biosciences Inc
Over the last 6 years, insiders at Aptose Biosciences Inc have traded over $2,827,381 worth of Aptose Biosciences Inc stock and bought 538,629 units worth $767,189 . The most active insiders traders include Erich Platzer, Bernd R. Seizinger, and William G. Rice. On average, Aptose Biosciences Inc executives and independent directors trade stock every 59 days with the average trade being worth of $14,277. The most recent stock trade was executed by Bernd R. Seizinger on 22 September 2023, trading 17,000 units of APTO stock currently worth $53,380.
What does Aptose Biosciences Inc do?
aptose biosciences is a science-driven biotechnology company advancing first-in-class agents to treat life-threatening cancers, such as acute myeloid leukemia (aml), high-risk myelodysplastic syndromes (mds) and other hematologic malignancies. based on insights into the genetic and epigenetic profiles of certain cancers and patient populations, aptose is building a pipeline of novel oncology therapies directed at dysregulated processes and signaling pathways. aptose is developing targeted medicines for precision treatment of these diseases, based on a patient’s specific gene expression signature. in the treatment of cancer, this strategy is intended to optimize efficacy and quality of life by minimizing the cytotoxic side effects associated with conventional therapies. cg026806 (cg’806) is a highly potent first-in-class pan-flt3/btk inhibitor. this small molecule therapeutic agent, exhibits a picomolar ic50 toward the fms-like tyrosine kinase 3 with the internal tandem duplication (flt
What does Aptose Biosciences Inc's logo look like?
Complete history of Erich Platzer stock trades at Aptose Biosciences Inc and CTI BioPharma Corp
Aptose Biosciences Inc executives and stock owners
Aptose Biosciences Inc executives and other stock owners filed with the SEC include:
-
William Rice,
Chairman of the Board, President, Chief Executive Officer -
Gregory Chow,
Chief Financial Officer, Executive Vice President -
Jotin Marango,
Senior Vice President, Chief Business Officer -
Dr. William G. Rice Ph.D.,
Chairman, Pres & CEO -
Dr. Jotin Marango Ph.D., M.D.,
Sr. VP, CFO, Chief Accounting Officer & Chief Bus. Officer -
Dr. Rafael Bejar M.D., Ph.D.,
Sr. VP & Chief Medical Officer -
Denis Burger,
Lead Independent Director -
Caroline Loewy,
Independent Director -
Carol Ashe,
Independent Director -
Warren Whitehead,
Independent Director -
Mark Vincent,
Independent Director -
Erich Platzer,
Independent Director -
Rafael Bejar,
Senior Vice President, Chief Medical Officer -
Roger Davies B.Sc.,
VP of Operations -
Bernd R. Seizinger,
-
Fletcher Payne,
Sr VP and CFO -
Philippe Ledru,